Here’s a polished English translation of the Chinese title: **”SUPER 2 Published in *Nature Communications*: Efsupaglutide Alpha Significantly Improves Blood Glucose and Elicits a Positive β-Cell Functional Response”**

Summary:
Led by Academician Jia Weiping and co-corresponded by Professor Wang Qinghua, SUPER 2 shows that Efsubaglutide alfa, on top of metformin, significantly improves glycemic control in patients with type 2 diabetes, and indicates improved β-cell function through metrics such as MMTT, HOMA-β, and disposition index, providing larger-sample clinical support for disease remission-related research.

ShanghaiMay 12, 2026 /PRNewswire/ — Recently, the results of the SUPER 2 study on Efsubaglutide alfa were published in the international authoritative journal Nature Communications.

Led by Academician Jia Weiping and co-corresponded by Professor Wang Qinghua, this study systematically evaluated the efficacy, safety, and β-cell function-related responses of Efsubaglutide alfa in patients with type 2 diabetes who had inadequate glycemic control on metformin therapy. The paper indicates that Professor Wang Qinghua’s affiliated institutions include Huashan Hospital of Fudan University and Shanghai Yinuo Pharmaceutical; Yinuo Pharmaceutical is a biopharmaceutical company focusing on innovative therapies for diabetes and other metabolic diseases, with Efsubaglutide alfa being one of its core products. ([Nature]^[1])

SUPER 2 is a randomized, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 clinical trial.

In the study, phase 2b participants received 1 mg, 3 mg, or placebo for 12 weeks. An independent committee selected the 3 mg dose for phase 3 based on efficacy and safety; phase 3 further compared the performance of Efsubaglutide alfa 3 mg versus placebo in a 24-week double-blind treatment period. Results showed that at 12 weeks in phase 2b, HbA1c decreased by 1.10% and 1.43% in the 1 mg and 3 mg groups, respectively; at 24 weeks in phase 3, HbA1c decreased by 1.80% in the Efsubaglutide alfa 3 mg group, with adverse events primarily being mild to moderate gastrointestinal reactions.

More notably, SUPER 2 not only revalidates the glucose-lowering efficacy but also further strengthens the mechanistic evidence for Efsubaglutide alfa at the β-cell function level.

The study incorporated the Mixed Meal Tolerance Test (MMTT) as a key assessment to observe dynamic changes in postprandial glucose, insulin, and C-peptide, and analyzed these alongside metrics such as HOMA-β, HOMA-IR, and Disposition Index (DI). Results showed that after Efsubaglutide alfa treatment, HOMA-β significantly increased, suggesting improved β-cell function; the insulin/glucagon ratio significantly increased; and the DI curve shifted significantly to the right, indicating enhanced overall glucose disposal capacity. The study also designated MMTT-derived glucose, insulin, and C-peptide AUC0–2h as important endpoints for more direct assessment of β-cell secretory response.

These results resonate significantly with our previously published Diabetes Remission study.

A related study published in Advances in Therapy showed that in treatment-naïve type 2 diabetes patients, after completing 52 weeks of Efsubaglutide alfa treatment, some patients achieved diabetes remission upon drug discontinuation; among them, improved HOMA-β post-treatment was associated with a higher probability of remission, suggesting that β-cell function recovery may be an important foundation for long-term remission. SUPER 2 now provides further mechanistic support in a more standardized, larger-sample population on background metformin therapy, making the scientific logic that “Efsubaglutide alfa not only lowers blood glucose but may also improve the underlying pathophysiology of the disease” more complete. ([ResearchGate]^[2])

Professor Wang Qinghua is currently a Distinguished Professor at Fudan University, as well as the founder of Yinuo Pharmaceutical and the inventor of Efsubaglutide alfa.

The publication of SUPER 2 in Nature Communications not only marks another significant milestone in the evidence-based research of Efsubaglutide alfa for type 2 diabetes but also highlights the value of deep integration between basic research, mechanistic studies, and clinical translation. For GLP-1 class drugs, this achievement helps drive the treatment goal from simply “controlling blood glucose” toward a new phase that places greater emphasis on β-cell function protection, disease progression intervention, and long-term benefits. ([Nature]^[1])